Study Validates the Cost-Effectiveness of EarlyCDT-Lung

May 25, 2018

Oncimmune’s EarlyCDT® technology for early lung cancer detection has been extensively documented in peer reviewed publications. The newly published “Cost Effectiveness of an Autoantibody Test (EarlyCDT-Lung) as an Aid to Early Diagnosis of Lung Cancer in Patients with Incidentally Detected Pulmonary Nodules” shows that the test is highly cost-effective for use in pulmonary nodules 8 to 30 mm that are in CT surveillance.

New Study Evaluates the Cost-Effectiveness of EarlyCDT-Lung

Many patients with intermediate-risk pulmonary nodules in the range 8 to 30mm diameter are followed by CT surveillance alone. The risk of cancer in these pulmonary nodules is 9.5%1.

Derek Weycker of Policy Analysis Inc (PIA) shows that the initial use of EarlyCDT-Lung—rather than just CT surveillance alone—can create better outcomes for intermediate-risk patients in a cost-effective manner.

The researchers hypothesized that the use of EarlyCDT-Lung might add life years at a cost-effective rate to intermediate-risk patients that would undergo just CT surveillance otherwise. The use of a decision analytic model allowed them to evaluate the use of the EarlyCDT autoantibody test versus CT surveillance alone.

The results of the model show that the lung cancer blood test delivers additional life years through diagnostic stage shift at a cost of about $24,500 per quality adjusted life year (QALY). This compares very favorably with the cost-effectiveness thresholds of $100,000 to $150,000, which are being advocated for currently, and the $50,000 per QALY that has long been held as a benchmark for the cost-effective use of scarce healthcare resources.

For more information about this study on pulmonary nodules, see the full research article. If you have specific questions about EarlyCDT-Lung or are interested in ordering tests for your patients, contact us today.
1Tanner NT, Aggarwal J, Gould MK, et al. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest 2015;148(6):1405-14


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept